Jo Ishizawa, M.D., Ph.D.
Department of Leukemia, Division of Cancer Medicine
About Dr. Jo Ishizawa
Dr. Ishizawa's first training and faculty appointment was in Japan, where he received his MD and PhD degrees. From 2004 to 2007, he worked at Keio University Hospital as an intern and resident followed by a one year training as clinical fellow in the Department of Hematology. In 2007, Dr. Ishizawa entered the PhD program and conducted his thesis work on investigating the role of the cell cycle regulator Cdh1 in the hematopoietic system and a mouse lymphoma model at Professor Hideyuki Saya's laboratory at Keio University. After receiving his PhD degree in 2011, Dr. Ishizawa moved back to clinical service work at an attending physician for two years while continuing his laboratory work as a physician scientist. In April 2013, Dr. Ishizawa joined MD Anderson as a postdoctoral fellow under the supervision of Dr. Michael Andreeff. Based on several translational research achievements on leukemia and lymphoma (e.g., pre-clinical study of MDM2 inhibition, correlative studies in clinical trials in MDM2 inhibitors, pre-clinical studies on organellar unfolded protein response), Dr. Ishizawa was promoted to Instructor in the Department of Leukemia in January 2017. Dr. Ishizawa's vision is to develop optimally effective treatments that will cure patients with hematological malignancies. To this end, his mission is to become an independent translational cancer researcher who is able to merge basic and clinical science. In this aspect, Dr. Ishizawa's research goal is to create novel therapeutic rationale to eliminate acute leukemia and aggressive lymphomas, currently focusing on mitochondrial biology and mechanisms of apoptosis in leukemia and lymphoma.
Read More
Present Title & Affiliation
Primary Appointment
Associate Professor, Leukemia, Term Tenure Track, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2011 | Keio University School of Medicine, Tokyo, JP, Hematology, Ph.D |
| 2004 | Keio University School of Medicine, Tokyo, JP, MD |
Postgraduate Training
| 2013-2017 | Postdoctoral Fellow, University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2007-2011 | Clinical Fellowship, Hematology, Keio University, Tokyo |
| 2006-2007 | Clinical Fellowship, Internal Medicine, Keio University School of Medicine, Tokyo |
| 2005-2006 | Clinical Residency, Japanese Red Cross Shizuoka Hospital, Shizuoka |
| 2004-2005 | Clinical Residency, Keio University Hospital, Tokyo |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Leukemia - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2021
Instructor, Leukemia - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2018
Collaborative Researcher, Hematology, Keio University, School of Medicine, Tokyo, 2016 - 2025
Instructor, Keio University Hospital, Division of Hematology, Tokyo, 2011 - 2013
Other Professional Positions
Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2017
Clinical Fellow, Keio University Hospital - Division of Hematology, Tokyo, 2007 - 2011
Clinical Fellow, Keio University Hospital - Internal Medicine, Tokyo, 2006 - 2007
Resident, Japanese Red Cross Shizuoka Hospital, Shizuoka, 2005 - 2006
Resident, Keio University Hospital, Tokyo, 2004 - 2005
Extramural Institutional Committee Activities
Member, Academic Review Committee for the Division of Education & Training, The University of Texas MD Anderson Cancer Center, 2022 - 2028
Honors & Awards
| 2019 | Rising Star Award, Keio University School of Medicine |
| 2019 | Young Investigator Award, Keio University School of Medicine Alumni Association |
| 2017 | Invited Speaker, The 76th Annual Meeting of the Japanese Cancer Association |
| 2015 | Abstract Achievement Award, American Society of Hematology |
| 2013 | Abstract Achievement Award, American Society of Hematology |
| 2011 | Selected as Co-Leader, Academy of Cancer Experts in Japan |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Mitochondrial Regulated Cell Death in Acute Myeloid Leukemia— Exploring the Clinical Potential of “Ferro-apoptosis” —. Invited. Leukemia Research Meeting. Houston, Texas, US.
- 2024. Ferroptosis in Acute Myeloid Leukemia. Invited. Leukemia Research Meeting. Houston, Texas, US.
- 2022. Targeting Ferroptosis and Mitochondrial pathways in AML/MDS. Invited. Leukemia Research Meeting. Houston, Texas, US.
Regional Presentations
- 2025. Perspectives on Spatial and Membranous Regulation of Leukemia Cell Death. Invited, JP.
- 2025. Mitochondrial Regulated Cell Death in Acute Myeloid Leukemia. Invited, JP.
- 2023. Targeting Mitochondrial Aldehyde Metabolism to Augment Vulnerability to Ferroptosis in Therapy Resistant Acute Myeloid Leukemia. Invited, JP.
- 2023. Targeting Mitochondrial Aldehyde Metabolism to Augment Vulnerability to Ferroptosis in Therapy Resistant Acute Myeloid Leukemia. Invited, JP.
International Presentations
- 2026. Ferroptosis in Acute Myeloid Leukemia: Convergence with Apoptosis. Invited. C8 Early Career Symposium.
- 2025. Dose intensive regimen of CK0804 tregs in myelofibrosis. Poster. American Society of Hematology 67th Annual Meeting and Exposition, US.
- 2025. Ferroptosis activates NK and CAR T cell-mediated anti-tumor immunity in Acute Myeloid Leukemia. Poster. American Society of Hematology 67th Annual Meeting and Exposition, US.
- 2025. A genome-wide CRISPR screen identifies conventional and novel ferroptosis regulators in Acute Myeloid Leukemia. Poster. American Society of Hematology 67th Annual Meeting and Exposition, US.
- 2025. A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician's choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in Acute Myeloid Leukemia. Poster. American Society of Hematology 67th Annual Meeting and Exposition, US.
- 2025. Unidirectional synergy between ferroptosis and apoptosis reveals a novel therapeutic strategy for refractory AML. Poster. American Society of Hematology 67th Annual Meeting and Exposition, US.
- 2025. Ferroptosis in Acute Myeloid Leukemia — Mitochondrial Regulation and Crosstalk with Apoptosis—. Invited, CA.
- 2025. Lipid-Droplet-mediated Lipid Remodeling in Ferroptosis in Acute Myeloid Leukemia. Invited. The 87th Annual Meeting of the Japanese Society of Hematology, JP.
- 2024. Targeting Lipid Droplet Biogenesis to Enhance Ferroptosis in Acute Myeloid Leukemia. Poster. American Society of Hematology 66th Annual Meeting and Exposition, US.
- 2024. A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia. Poster. American Society of Hematology 66th Annual Meeting and Exposition, US.
- 2024. A phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib. Poster. American Society of Clinical Oncology Annual Meeting 2024, US.
- 2024. Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission. Poster. American Society of Hematology 66th Annual Meeting and Exposition, US.
- 2024. A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib. Poster. American Society of Hematology 66th Annual Meeting and Exposition, US.
- 2024. Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL). Poster. American Society of Hematology 66th Annual Meeting and Exposition, US.
- 2024. Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies. Poster. American Society of Hematology 66th Annual Meeting and Exposition, US.
- 2024. Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials. Poster. American Society of Hematology 66th Annual Meeting and Exposition, US.
- 2024. Molecular Interactions between Mitochondrial Ferroptosis and Apoptosis Pathways in Acute Myeloid Leukemia. Poster. American Society of Hematology 66th Annual Meeting and Exposition, US.
- 2024. Isolation of Lipid Droplets from Acute Myeloid Leukemia Cells for Lipidomic Analysis. Poster. American Society of Hematology 66th Annual Meeting and Exposition, US.
- 2024. Targeting Ferroptosis-Apoptosis Interplay For Acute Myeloid Leukemia Therapy. Invited. The 86th Annual Meeting of the Japanese Society of Hematology, JP.
- 2023. Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study. Poster. American Society of Hematology 65th Annual Meeting and Exposition, US.
- 2023. A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib. Poster. American Society of Hematology 65th Annual Meeting and Exposition, US.
- 2023. Mitophagy As a Novel Cell-Protective Mechanism Against Mitochondrial Ferroptosis in Acute Myeloid Leukemia. Poster. American Society of Hematology 65th Annual Meeting and Exposition, US.
- 2023. Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results. Poster. American Society of Hematology 65th Annual Meeting and Exposition, US.
- 2023. Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria. Poster. American Society of Hematology 65th Annual Meeting and Exposition, US.
- 2023. Targeting Aldehyde Dehydrogenase To Enhance Mitochondrial Ferroptosis in Acute Myeloid Leukemia. Invited. The 87th Annual Meeting of the Japanese Society of Hematology, JP.
- 2022. Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia. Poster. American Society of Hematology 64th Annual Meeting and Exposition, US.
- 2022. Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia. Poster. American Society of Hematology 64th Annual Meeting and Exposition, US.
- 2022. The Triple Inhibition of MDM2, XPO1 and BCL-2 Profoundly Induce Cell Kill in Ven/HMA Resistant AML. Invited. The 84th Annual Meeting of the Japanese Society of Hematology, US.
- 2022. Synergistic Induction of Mitochondria-Regulated Ferroptotic Cell Death in Acute Myeloid Leukemia. Invited. Japanese Society of Hematology, JP.
- 2021. Dual Targeting of Glutathione-GPX4 Nexus and Mitochondrial Protease CLPP Causes Synergistic Anti-Leukemia Effects in Acute Myeloid Leukemia (AML). Poster. American Society of Hematology 63th Annual Meeting and Exposition, US.
- 2021. Therapeutic Targeting of Ferroptosis Pathway in Combination With Mitochondrial Oxidative Stress Induction in Acute Myeloid Leukemia. Poster. American Society of Hematology 63th Annual Meeting and Exposition, US.
- 2021. Dual Targeting of Glutathione-GPX4 Nexus and Mitochondrial Protease CLPP Causes Synergistic Anti-Leukemia Effects in Acute Myeloid Leukemia (AML). Poster. AACR Annual Meeting 2021, US.
- 2021. Dual Targeting of Selenoprotein GPX4 and Mitochondrial ClpP Causes Synergistic Anti-Leukemia Effects. Invited. 83rd Annual Meeting of the Japanese Society of Hematology, US.
- 2021. Glutathione-GPX4 Nexus Protects Acute Myeloid Leukemia (AML) Cells From Mitochondrial Protease ClpP-induced Cell Killing. Invited. 80th Annual Meeting of the Japanese Cancer Association, JP.
- 2020. Clonoal Expansion of P53 Mutant Cells by MDM2 Inhibition in Acute Myeloid Leukemias. Poster. 62nd Annual Meeting and Exposition of the American Society of Hematology, US.
- 2020. Exportin-1 (SPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-type p53 Acute Myeloid Leukemias. Poster. 62nd Annual Meeting and Exposition of the American Society of Hematology, US.
- 2019. Dual Targeting of mitochondrial unfolded protein response and BCL2 in acute myeloid leukemia. Poster. 61st Annual Meeting and Exposition of the American Society of Hematology, US.
- 2018. The novel imipridone ONC212 highly synergizes with the BCL-2 inhibitor ABT-199 in AML and activates orphan receptor GPR132. Poster. 105th Annual Meeting of the American Association for Cancer Research, US.
- 2018. TP73 isoforms (TAp73 and delta-Np73) are overexpressed in acute myeloid leukemias and potential therapeutic targets to enhance anti-leukemia activities of Bcl-2 and MDM2 inhibitors. Poster. American Society of Hematology 60th Annual Meeting and Exposition, US.
- 2017. Inhibition of Translation Initiation and Heat Shock Factor 1 (HSF1): a novel strategy targeting FLT3 double mutant and non-FLT3 mutant AML progenitor/stem cells. Poster. 61st Annual Meeting and Exposition of the American Society of Hematology, US.
- 2017. The novel imipridone ONC212 induces pronounced anti-leukemia effects in vitro and in vivo and is highly synergistic with the Bcl-2 inhibitor ABT-199. Poster. 59th Annual Meeting and Exposition of the American Society of Hematology, US.
- 2016. Discovery of predictive gene signatures for tumor sensitivity to MDM2 inhibition in development of a novel MDM2 inhibitor DS-3032b. Poster. 58th Annual Meeting and Exposition of the American Society of Hematology, US.
- 2016. A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias. Poster. 58th Annual Meeting and Exposition of the American Society of Hematology, US.
- 2016. Targeting Aggregation of Wilde-Type p53 and Mutant p53 with ReACp53 As a Novel Therapeutic Concept for AML. Poster. 58th Annual Meeting and Exposition of the American Society of Hematology, US.
- 2016. The Novel Thiosemicarbazone Derivative Coti-2 Induces Mitochondrial Apoptosis in Acute Myeloid Leukemia Cells Via a p53-Independent Mechanism. Poster. 58th Annual Meeting and Exposition of the American Society of Hematology, US.
- 2016. ONC212 Is a Potent Member of the Imipridone Class of Anti-Cancer Compounds That Induces p53-Independent Apoptosis in Hematological Malignancies. Poster. 58th Annual Meeting and Exposition of the American Society of Hematology, US.
- 2015. Inactivating Heat Shock Factor 1 (HSF1) in Acute Myeloid Leukemia by Pharmacological Inhibition of eIF4a: A Promising Therapeutic Approach. Poster. 59th Annual Meeting and Exposition of the American Society of Hematology, US.
- 2015. Gene expression and TP53 mutation analysis predict sensitivity of leukemia cells to MDM2 inhibition by DS-3032b. Poster. AACR‑NCI‑EORTC International Conference on Molecular Targets and Cancer Therapeutics, US.
- 2015. Combinatorial Targeting of XPO1 and FLT3-ITD Exerts Synergistic Anti-Tumor Effects in FLT3-Mutated Acute Myeloid Leukemias. Poster. 59th Annual Meeting and Exposition of the American Society of Hematology, US.
- 2015. ONC201 Induces p53-independent apoptosis and abrogates Stem Cell Function in Hematological Malignancies by Induction of ATF4 Through Integrated Stress Response. Poster. 59th Annual Meeting and Exposition of the American Society of Hematology, US.
- 2014. ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition. Poster. 56th Annual Meeting & Exposition of the American Society of Hematology, US.
- 2014. Prognostic Impact and Targeting of BMI-1 in Acute Myeloid Leukemia. Poster. 56th Annual Meeting & Exposition of the American Society of Hematology, US.
- 2014. ONC201 Possesses a Benign Safety Profile at Highly Efficacious Doses in Normal Human Cells and Animal Toxicology Studies. Poster. 56th Annual Meeting & Exposition of the American Society of Hematology, US.
- 2014. ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples. Poster. 56th Annual Meeting & Exposition of the American Society of Hematology, US.
- 2014. Mitochondrial Priming of New Targeted Agents in Acute Myeloid Leukemia. Poster. 105th Annual Meeting of the American Association for Cancer Research, US.
- 2013. Induction Of p53 Transcription and Apoptosis By XPO1 Inhibition In Mantle Cell Lymphoma. Poster. 55th Annual Meeting and Exposition of the American Society of Hematology, US.
- 2013. ONC201 Exerts p53-Independent Cytotoxicity Through TRAIL and DR5 Induction In Mantle Cell Lymphomas. Poster. 55th Annual Meeting and Exposition of the American Society of Hematology, US.
- 2013. Loss of Function of The Cell Cycle Regulator Cdh1 Causes Cell Fragility due to Aberrant G2/M Checkpoint and Develops Resistant Disease in a B-ALL/LBL Mouse Model. Invited. 55th Annual Meeting and Exposition of the American Society of Hematology, US.
- 2012. Detailed Investigation On Characteristics of Japanese Patients with Chronic Phase CML Who Achieved a Durable CMR After Discontinuation of Imatinib – an Updated Result of the Keio STIM Study. Poster. 54th Annual Meeting and Exposition of the American Society of Hematology, US.
- 2011. Arf and Ink4a Are Critical Factors Determining the Cell of Origin and Therapeutic Sensitivity in Myc-Induced Mouse Lymphoid Tumor. Poster. 62nd Annual Meeting and Exposition of the American Society of Hematology, US.
- 2011. Discontinuation of Imatinib in Patients with CML and Sustained Complete Molecular Response (CMR) for Over 2 Years in the Japanese Population – An Interim Analysis of KEIO STIM Study. Poster. 62nd Annual Meeting and Exposition of the American Society of Hematology, US.
- 2011. Role of the Cell Cycle Regulator Cdh1 in Physiology and Pathology of Hematopoiesis. Poster. 62nd Annual Meeting and Exposition of the American Society of Hematology, US.
Grant & Contract Support
| Date: | 2026 - 2028 |
| Title: | Ferroptosis-Driven Anti-Tumor Immunity as Novel Therapeutic Strategy in Acute Myeloid Leukemia |
| Funding Source: | American Cancer Society |
| Role: | PI |
| ID: | FP00026826 |
| Date: | 2025 - 2026 |
| Title: | Therapeutic Induction of Ferroptosis and Lipid Remodeling in Therapy-Resistant Acute Myeloid Leukemia |
| Funding Source: | Elsa U. Pardee Foundation |
| Role: | PI |
| ID: | FP00024917 |
| Date: | 2025 - 2026 |
| Title: | Harnessing Ferroptosis-mediated Anti-leukemic immune Response for Developing a Novel Therapeutic Strategy in Acute Myeloid Leukemia |
| Funding Source: | The U Foundation |
| Role: | PI |
| ID: | FP00025795 |
| Date: | 2023 - 2026 |
| Title: | Targeting Ferroptosis and Mitochondrial Pathways in Acute Myeloid Leukemia |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | CA220581 |
| Date: | 2022 - 2027 |
| Title: | An Integrated Approach towards Improving Outcomes in Higher Risk Myelodysplastic Syndromes / Project 3: Targeting the Ferroptosis and Apoptosis Pathways in Therapy-Resistant High-Risk MDS |
| Funding Source: | The University of Texas MD Anderson Multidisciplinary Research Program |
| Role: | Co-PI |
| ID: | FP00016057 |
| Date: | 2022 - 2024 |
| Title: | Targeting AML Mitochondria by Ceramide |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R41CA275631 |
| Date: | 2022 - 2023 |
| Title: | Ferroptosis-based Therapy in Acute Myeloid Leukemia |
| Funding Source: | Leukemia SPORE Developmental Research Program (DRP) |
| Role: | PI |
| ID: | FP00018294 |
| Date: | 2022 - 2023 |
| Title: | Targeting Mitochondrial Anti-Lipid Peroxidation to Induce Ferroptosis in Therapy Resistant AML |
| Funding Source: | Leukemia Research Foundation |
| Role: | PI |
| ID: | 964182 |
| Date: | 2022 - 2023 |
| Title: | Therapeutic targeting of p53 reactivation-induced OXPHOS dependency and stress responses to overcome resistance to venetoclax/HMA in AML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R21 CA267401-01 |
| Date: | 2022 - 2024 |
| Title: | Mitochondrial Ferroptosis in Acute Myeloid Leukemia |
| Funding Source: | UTMDACC Institutional Research Grant |
| Role: | PI |
| ID: | RCTS 57691 |
| Date: | 2020 - 2021 |
| Title: | Targeting mitochondrial proteostasis and prosurvival redox system in p53-mutated acute myeloid |
| Funding Source: | UTMDACC Institutional Research Grant |
| Role: | Co-I |
| ID: | RCTS 57691 |
| Date: | 2019 - 2027 |
| Title: | Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014) |
| Funding Source: | Food and Drug Administration (FDA) |
| Role: | Co-PI |
| ID: | 1 R01 FD006118-01A1 |
| Date: | 2019 - 2021 |
| Title: | Targeting the mitochondrial protease ClpP, as a novel therapeutic strategy for AML |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Co-I |
| ID: | LLS TRP 6599-20 |
| Date: | 2019 - 2020 |
| Title: | Strategic Alliance: Combinatorial Inhibition of MDM2 and XPO1 in AML |
| Funding Source: | Daiichi-Sankyo, Inc |
| Role: | Co-I |
| ID: | RCTS 57095 |
| Date: | 2018 - 2019 |
| Title: | SPORE DRP: Combined blockade of MDM2 and XPO1 in acute myeloid leukemia |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P50 CA100632 |
| Date: | 2016 - 2021 |
| Title: | Flagship Project: Targeting Minimal Residual Disease and Stem-like Cells in High-Risk AML |
| Funding Source: | MDACC Moon Shot Program |
| Role: | Co-I |
| Date: | 2016 - 2018 |
| Title: | SPORE CEP: Therapeutically targeting mitochondrial protein transport in Acute Myeloid Leukemia: A novel mechanism of action of first-in-class Imipridone ONC201 |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P50 CA100632 |
| Date: | 2013 - 2018 |
| Title: | Leukemia SPORE (Project 3: p53 activation as novel therapeutic strategy for acute myelogenous leukemia) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 P50 CA100632 |
| Date: | 2013 - 2015 |
| Title: | Postdoctoral Fellowship for Research Abroad |
| Funding Source: | Japanese Society for the Promotion of Science |
| Role: | Postdoctoral Fellow |
| Date: | 2012 - 2013 |
| Title: | "Analysis of the cell fragility due to loss of cell cycle regulator Cdh1 in adult hematopoiesis and hematological malignancies using conditional Cdh1 gene-trap mice" |
| Funding Source: | Ministry of Education, Culture, Sports, Science and Technology |
| Role: | Co-I |
| ID: | Grant-in-Aid for Young Scientists (B) |
| Date: | 2010 - 2012 |
| Title: | "Analysis of the cell cycle regulator Cdh1 function in adult hematopoiesis using conditional Cdh1 gene-trap mice" |
| Funding Source: | Ministry of Education, Culture, Sports, Scence and Technology |
| Role: | Co-I |
| ID: | Grant-in-Aid for Young Scientists (B) |
| Date: | 2010 - 2011 |
| Title: | "Analysis of the cell cycle regulator Cdh1 function in B cell malignancy" |
| Funding Source: | Ministry of Education, Culture, Sports, Science and Technology |
| Role: | Co-I |
| ID: | Grant-in-Aid for Global COE Research |
| Date: | 2009 - 2010 |
| Title: | "Analysis of the cell cycle regulator Cdh1 function in adult hematopoiesis using conditional Cdh1 gene-trap mice" |
| Funding Source: | Ministry of Education, Culture, Sports, Science and Technology |
| Role: | Co-I |
| ID: | Grant-in-Aid for Global COE Research |
| Date: | 2008 - 2009 |
| Title: | "Investigation of endoduplication therapy by manipulating the cell cycle regulator Cdh1, targeting cancer stem cells" |
| Funding Source: | Ministry of Education, Culture, Sports, Science and Techology |
| Role: | Co-I |
| ID: | Grant-in-Aid for Global COE Research |
| Date: | 2008 - 2009 |
| Title: | "Clinical analysis of the factors causing the difference of growth between individual patients with hematological malignancies" |
| Funding Source: | Ministry of Education, Culture, Sports, Science and Techology |
| Role: | Co-I |
| ID: | Grant-in-Aid for teh 21st Century COE Program |
Selected Publications
Peer-Reviewed Articles
- Zhao, R, Zhang, L, Dong, S, Kamachi, K, Gupta, SK, Akiyama, H, Nguyen, J, Hackman, GL, Andreeff, M, Lodi, A, Ishizawa, J. Protocol for isolation of lipid droplets and mitochondria from acute myeloid leukemia cells for lipidomic analysis. STAR Protocols 6(4), 2025. e-Pub 2025. PMID: 41420867.
- Akiyama H, Kantarjian H, Jabbour E, Issa G, Haddad FG, Short NJ, Hu S, Ishizawa J, Andreeff M, Sasaki K. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia. Int J Hematol 120(2):203-211, 2024. e-Pub 2024. PMID: 38748089.
- Akiyama H, Zhao R, Ostermann LB, Li Z, Tcheng M, Yazdani SJ, Moayed A, Pryor ML 2nd, Slngh S, Baran N, Ayoub E, Nishida Y, Mak PY, Ruvolo VR, Carter BZ, Schimmer AD, Andreeff M, Ishizawa J. Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia. Leukemia 38(4):729-740, 2024. e-Pub 2024. PMID: 38148395.
- Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
- Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv 9(48):eadh1436, 2023. e-Pub 2023. PMID: 38019903.
- Glytsou C, Chen X, Zacharioudakis E, Al-Santli W, Zhou H, Nadorp B, Lee S, Lasry A, Sun Z, Papaioannou D, Cammer M, Wang K, Zal T, Zal MA, Carter BZ, Ishizawa J, Tibes R, Tsirigos A, Andreeff M, Gavathiotis E, Aifantis I. Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Discov 13(7):1656-1677, 2023. e-Pub 2023. PMID: 37088914.
- Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
- Fan Y, Li Y, Yao X, Jin J, Scott A, Liu B, Wang S, Huo L, Wang Y, Wang R, Pool Pizzi M, Ma L, Shao S, Sewastjanow-Silva M, Waters R, Chatterjee D, Liu B, Shanbhag N, Peng G, Calin GA, Mazur PK, Hanash SM, Ishizawa J, Hirata Y, Nagano O, Wang Z, Wang L, Xian W, McKeon F, Ajani JA, Song S. Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment. Gut 72(4):624-637, 2023. e-Pub 2023. PMID: 36002248.
- Nishida Y, Zhao R, Heese LE, Akiyama H, Patel S, Jaeger AM, Jacamo RO, Kojima K, Ma MCJ, Ruvolo VR, Chachad D, Devine W, Lindquist S, Davis RE, Porco JA Jr, Whitesell L, Andreeff M, Ishizawa J. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. Leukemia 35(9):2469-2481, 2021. e-Pub 2021. PMID: 34127794.
- Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, Allen JE, Oster W, Stogniew M, Ishizawa J, Andreeff M. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia 33(12):2805-2816, 2019. e-Pub 2019. PMID: 31127149.
- Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell 35(5):721-737.e9, 2019. e-Pub 2019. PMID: 31056398.
- Piya S, Mu H, Bhattacharya S, Lorenzi PL, Davis RE, McQueen T, Ruvolo V, Baran N, Wang Z, Qian Y, Crews CM, Konopleva M, Ishizawa J, You MJ, Kantarjian H, Andreeff M, Borthakur G. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. J Clin Invest 129(5):1878-1894, 2019. e-Pub 2019. PMID: 30829648.
- Zhang W, Ly C, Ishizawa J, Mu H, Ruvolo V, Shacham S, Daver N, Andreeff M. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103(10):1642-1653, 2018. e-Pub 2018. PMID: 29773601.
- Maeda A, Nishida Y, Weetall M, Cao L, Branstrom A, Ishizawa J, Nii T, Schober WD, Abe Y, Matsue K, Yoshimura M, Kimura S, Kojima K. Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma. Oncotarget 9(47):28547-28560, 2018. e-Pub 2018. PMID: 29983879.
- Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese L, Ma W, Ma MCJ, DiNardo C, Pierce S, Patel KP, Tse A, Davis RE, Rao A, Andreeff M. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78(10):2721-2731, 2018. e-Pub 2018. PMID: 29490944.
- Tu YS, He J, Liu H, Lee HC, Wang H, Ishizawa J, Allen JE, Andreeff M, Orlowski RZ, Davis RE, Yang J. The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma. Neoplasia 19(10):772-780, 2017. e-Pub 2017. PMID: 28863346.
- Ishizawa J, Sugihara E, Kuninaka S, Mogushi K, Kojima K, Benton CB, Zhao R, Chachad D, Hashimoto N, Jacamo RO, Qiu Y, Yoo SY, Okamoto S, Andreeff M, Kornblau SM, Saya H. FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia. Blood 129(14):1958-1968, 2017. e-Pub 2017. PMID: 28143883.
- Tabe Y, Yamamoto S, Saitoh K, Sekihara K, Monma N, Ikeo K, Mogushi K, Shikami M, Ruvolo V, Ishizawa J, Hail N Jr, Kazuno S, Igarashi M, Matsushita H, Yamanaka Y, Arai H, Nagaoka I, Miida T, Hayashizaki Y, Konopleva M, Andreeff M. Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells. Cancer Res 77(6):1453-1464, 2017. e-Pub 2017. PMID: 28108519.
- Nishida Y, Maeda A, Kim MJ, Cao L, Kubota Y, Ishizawa J, AlRawi A, Kato Y, Iwama A, Fujisawa M, Matsue K, Weetall M, Dumble M, Andreeff M, Davis TW, Branstrom A, Kimura S, Kojima K. The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells. Blood Cancer J 7(2):e527, 2017. e-Pub 2017. PMID: 28211885.
- Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal 9(415):ra17, 2016. e-Pub 2016. PMID: 26884599.
- Nishida Y, Maeda A, Chachad D, Ishizawa J, Qiu YH, Kornblau SM, Kimura S, Andreeff M, Kojima K. Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy. Cancer Sci 106(12):1705-13, 2015. e-Pub 2015. PMID: 26450753.
- Ishizawa J, Kojima K, McQueen T, Ruvolo V, Chachad D, Nogueras-Gonzalez GM, Huang X, Pierceall WE, Dettman EJ, Cardone MH, Shacham S, Konopleva M, Andreeff M. Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs. PLoS One 10(9):e0138377, 2015. e-Pub 2015. PMID: 26375587.
- Tabe Y, Kojima K, Yamamoto S, Sekihara K, Matsushita H, Davis RE, Wang Z, Ma W, Ishizawa J, Kazuno S, Kauffman M, Shacham S, Fujimura T, Ueno T, Miida T, Andreeff M. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185. PLoS One 10(9):e0137210, 2015. e-Pub 2015. PMID: 26340096.
- Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintas-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, Andreeff M, Kojima K. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci 105(7):795-801, 2014. e-Pub 2014. PMID: 24766216.
- Naoe H, Chiyoda T, Ishizawa J, Masuda K, Saya H, Kuninaka S. The APC/C activator Cdh1 regulates the G2/M transition during differentiation of placental trophoblast stem cells. Biochem Biophys Res Commun 430(2):757-62, 2013. e-Pub 2013. PMID: 23206702.
- Ueda T, Iino R, Yokoyama K, Okamoto S, Asakura K, Tsukada Y, Ishizawa J, Matsuki E, Ikeda Y, Hattori Y. Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma: a feasibility study in Japanese population. Int J Hematol 96(4):477-84, 2012. e-Pub 2012. PMID: 22949139.
- Sugihara E, Shimizu T, Kojima K, Onishi N, Kai K, Ishizawa J, Nagata K, Hashimoto N, Honda H, Kanno M, Miwa M, Okada S, Andreeff M, Saya H. Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor. Oncogene 31(23):2849-61, 2012. e-Pub 2012. PMID: 21986948.
- Ishizawa J, Mori T, Tsukada Y, Matsuki E, Yokoyama K, Shimizu T, Sugita K, Murata M, Iwata S, Okamoto S. [Recurrent cellulitis due to Helicobacter cinaedi after chemotherapy for malignant lymphoma]. Rinsho Ketsueki 53(6):623-7, 2012. e-Pub 2012. PMID: 22790638.
- Chiyoda T, Sugiyama N, Shimizu T, Naoe H, Kobayashi Y, Ishizawa J, Arima Y, Tsuda H, Ito M, Kaibuchi K, Aoki D, Ishihama Y, Saya H, Kuninaka S. LATS1/WARTS phosphorylates MYPT1 to counteract PLK1 and regulate mammalian mitotic progression. J Cell Biol 197(5):625-41, 2012. e-Pub 2012. PMID: 22641346.
- Kobayashi Y, Shimizu T, Naoe H, Ueki A, Ishizawa J, Chiyoda T, Onishi N, Sugihara E, Nagano O, Banno K, Kuninaka S, Aoki D, Saya H. Establishment of a choriocarcinoma model from immortalized normal extravillous trophoblast cells transduced with HRASV12. Am J Pathol 179(3):1471-82, 2011. e-Pub 2011. PMID: 21787741.
- Ishizawa J, Kuninaka S, Sugihara E, Naoe H, Kobayashi Y, Chiyoda T, Ueki A, Araki K, Yamamura K, Matsuzaki Y, Nakajima H, Ikeda Y, Okamoto S, Saya H. The cell cycle regulator Cdh1 controls the pool sizes of hematopoietic stem cells and mature lineage progenitors by protecting from genotoxic stress. Cancer Sci 102(5):967-74, 2011. e-Pub 2011. PMID: 21255192.
- Naoe H, Araki K, Nagano O, Kobayashi Y, Ishizawa J, Chiyoda T, Shimizu T, Yamamura K, Sasaki Y, Saya H, Kuninaka S. The anaphase-promoting complex/cyclosome activator Cdh1 modulates Rho GTPase by targeting p190 RhoGAP for degradation. Mol Cell Biol 30(16):3994-4005, 2010. e-Pub 2010. PMID: 20530197.
- Ishizawa J, Fujita H, Iguchi M, Tachibana T, Taguchi J, Ishigatsubo Y. Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir. Int J Hematol 85(3):242-5, 2007. e-Pub 2007. PMID: 17483062.
- Ishizawa J, Yoshida S, Oya M, Mizuno R, Shinojima T, Marumo K, Murai M. Inhibition of the ubiquitin-proteasome pathway activates stress kinases and induces apoptosis in renal cancer cells. Int J Oncol 25(3):697-702, 2004. e-Pub 2004. PMID: 15289872.
Review Articles
- Akiyama H, Carter BZ, Andreeff M, Ishizawa J. Molecular Mechanisms of Ferroptosis and Updates of Ferroptosis Studies in Cancers and Leukemia. Cells 12(8), 2023. e-Pub 2023. PMID: 37190037.
- Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 7(45):74380-74392, 2016. e-Pub 2016. PMID: 27602582.
- Kojima K, Ishizawa J, Andreeff M. Pharmacological activation of wild-type p53 in the therapy of leukemia. Exp Hematol 44(9):791-798, 2016. e-Pub 2016. PMID: 27327543.
- Ishizawa J, Kojima K, Hail N Jr, Tabe Y, Andreeff M. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. Pharmacol Ther 153:25-35, 2015. e-Pub 2015. PMID: 26048327.
- Ishizawa J, Saya H. [Current clinical trials using new targeted therapies for myeloid leukemia and the research trends]. Nihon Rinsho 67(10):1932-7, 2009. e-Pub 2009. PMID: 19860193.
Other Articles
- Akiyama H, Zhao R, Ostermann LB, Li Z, Tcheng M, Yazdani SJ, Moayed A, Pryor ML 2nd, Slngh S, Baran N, Ayoub E, Nishida Y, Mak PY, Ruvolo VR, Carter BZ, Schimmer AD, Andreeff M, Ishizawa J Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia. Leukemia 38(4):926, 2024. PMID: 38459170.
- Allen JE, Kline CLB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS Correction: Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 12(21):2231, 2021. PMID: 34676056.
Abstracts
- Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ruvolo VR, Yee MP, Carter BZ, Kojima K, Daver N, Lesegretain A, Shacham S, Andreeff M. Exportin-1 (SPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-type p53 Acute Myeloid Leukemias. Blood 136, Suppl 1:23-24, 2020. e-Pub 2020.
- Chachad D, Ishizawa J, Danter WR, Mills G, Andreeff M, Kojima K. The Novel Thiosemicarbazone Derivative Coti-2 Induces Mitochondrial Apoptosis in Acute Myeloid Leukemia Cells Via a p53-Independent Mechanism. Blood 128, 2016. e-Pub 2016.
- Zeng J, Soragni A, Ishizawa J, Ruvolo V, Benton CB, McQueen T, Ruvolo P, Qi Y, Su X, Burks J, Eisenberg DS, Andreeff M. Targeting Aggregation of Wilde-Type p53 and Mutant p53 with ReACp53 As a Novel Therapeutic Concept for AML. Blood 128, 2016. e-Pub 2016.
- Ishizawa J, Nakamaru K, Tazaki K, Seki T, Kojima K, Chachad D, DiNardo C, Pierce S, Patel KP, Tse A, Davis RE, Rao A, Andreeff M. Discovery of predictive gene signatures for tumor sensitivity to MDM2 inhibition in development of a novel MDM2 inhibitor DS-3032b. Blood 128, 2016. e-Pub 2016.
- Borthakur G, Ishizawa J, DiNardo CD, Kadia TM, Weise K, Allen JE, Oster W, Cortes JE, Kantarjian HM, Andreeff M. A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias. Blood 128, 2016. e-Pub 2016.
- Nii T, Ishizawa J, Zhao R, Zeng J, Chachad D, Kojima K, Konopleva M, Davis RE, Allen JE, Stogniew M, Andreeff M. ONC212 Is a Potent Member of the Imipridone Class of Anti-Cancer Compounds That Induces p53-Independent Apoptosis in Hematological Malignancies. Blood 128, 2016. e-Pub 2016.
- Ishizawa J, Jacamo RO, Kojima K, Chachad D, Ruvolo V, Ruvolo P, Zhang W, Tabe Y, Konopleva M, Devine W, Lindquist S, Porco JA, Jr, Whitesell L, Andreeff M. Inactivating Heat Shock Factor 1 (HSF1) in Acute Myeloid Leukemia by Pharmacological Inhibition of eIF4a: A Promising Therapeutic Approach. Blood 126, 2015. e-Pub 2015.
- Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski RZ, Sarbassov D, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ONC201 Induces p53-independent apoptosis and abrogates Stem Cell Function in Hematological Malignancies by Induction of ATF4 Through Integrated Stress Response. Blood 126, 2015. e-Pub 2015.
- Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Tse A, Rao A, Andreeff M. Gene expression and TP53 mutation analysis predict sensitivity of leukemia cells to MDM2 inhibition by DS-3032b. AACR-NCI-EORTC Intl Conf, 2015. e-Pub 2015.
- Zhang W, Ishizawa J, Mu H, Daver N, Ruvolo V, Andreeff M. Combinatorial Targeting of XPO1 and FLT3-ITD Exerts Synergistic Anti-Tumor Effects in FLT3-Mutated Acute Myeloid Leukemias. Blood 126, 2015. e-Pub 2015.
- Ishizawa J, Kojima K, Duvvuri SR, McQueen T, Ruvolo VR, Nogueras-Gonzalez GM, Huang X, Pierceall W, Cardone M, Lena R, Doykan C, Shacham S, Kauffman M, Konopleva M, Andreeff M. Mitochondrial Priming of New Targeted Agents in Acute Myeloid Leukemia. AACR, 2014. e-Pub 2014.
- Prabhu VV, Ishizawa J, Zhao D, Allen JE, Batchelor TT, Chi AS, Andreeff M, El-Deiry WS. ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples. Blood 124, 2014. e-Pub 2014.
- Nishida Y, Kojima K, Maeda A, Chachad D, Kitamura H, Ishizawa J, Andreef M, Kornblau SM, Kimura S. Prognostic Impact and Targeting of BMI-1 in Acute Myeloid Leukemia. Blood 124, 2014. e-Pub 2014.
- Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo VR, Jacamo R, Dilip A, Mu H, Zeng Z, Matre P, Allen JE, Neelapu SS, McDonnell TJ, Miranda RN, Kwak LW, Kantarjian HM, Konopleva M, Davis RE, Andreeff M. ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition. Blood 124, 2014. e-Pub 2014.
- Allen JE, Ishizawa J, El-Deiry WS, Andreeff M. ONC201 Possesses a Benign Safety Profile at Highly Efficacious Doses in Normal Human Cells and Animal Toxicology Studies. Blood 124, 2014. e-Pub 2014.
- Ishizawa J, Kojima K, Dilip A, Ruvolo VR, Carter BZ, Allen JE, Neelapu SS, McDonnell TJ, Talekar MK, El-Deiry WS, Kwak LW, Andreeff M. ONC201 Exerts p53-Independent Cytotoxicity Through TRAIL and DR5 Induction In Mantle Cell Lymphomas. Blood 122, 2013. e-Pub 2013.
- Yoshimura M, Ishizawa J, Dilip A, Shacham S, Kauffman M, Tabe Y, Kimura S, Andreeff M, Kojima K. Induction Of p53 Transcription and Apoptosis By XPO1 Inhibition In Mantle Cell Lymphoma. Blood 122, 2013. e-Pub 2013.
- Ishizawa J, Sugihara E, Hashimoto N, Kuninaka S, Kojima K, Andreeff M, Okamoto S, Saya H. Loss of Function of The Cell Cycle Regulator Cdh1 Causes Cell Fragility due to Aberrant G2/M Checkpoint and Develops Resistant Disease in a B-ALL/LBL Mouse Model. Blood 122, 2013. e-Pub 2013.
- Matsuki E, Ono Y, Tonegawa K, Sakurai M, Kunimoto H, Ishizawa J, Hashimoto N, Shimizu T, Yamane A, Matsushita M, Yokoyama K, Okamoto S. Detailed Investigation On Characteristics of Japanese Patients with Chronic Phase CML Who Achieved a Durable CMR After Discontinuation of Imatinib – an Updated Result of the Keio STIM Study. Blood 120, 2012. e-Pub 2012.
- Sugihara E, Shimizu T, Kojima K, Ishizawa J, Andreeff M, Saya H. Arf and Ink4a Are Critical Factors Determining the Cell of Origin and Therapeutic Sensitivity in Myc-Induced Mouse Lymphoid Tumor. Blood 118, 2011. e-Pub 2011.
- Matsuki E, Ono Y, Sakurai M, Kunimoto H, Ishizawa J, Shimizu T, Yamane A, Matsushita M, Yokoyama K, Okamoto S. Discontinuation of Imatinib in Patients with CML and Sustained Complete Molecular Response (CMR) for Over 2 Years in the Japanese Population – An Interim Analysis of KEIO STIM Study,. Blood 118, 2011. e-Pub 2011.
- Ishizawa J, Sugihara E, Hashimoto N, Kuninaka S, Okamoto S, Saya H. Role of the Cell Cycle Regulator Cdh1 in Physiology and Pathology of Hematopoiesis. Blood 118, 2011. e-Pub 2011.
Letters to the Editor
- Azevedo, RS, Braish, J, Gener-Ricos, G, Tang, G, Sasaki, K, Montalban Bravo, G, Jabbour, EJ, Ohanian, M, Yilmaz, M, Haddad, FG, Chien, KS, Ishizawa, J, Short, NJ, Maiti, A, Swaminathan, M, Kantarjian, HM, Borthakur, G, Kadia, TM. Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia. Leukemia and Lymphoma 67: 220-224, 2026.
Patient Reviews
CV information above last modified September 11, 2026